Janssen

News

J&J builds case for antidepressant Spravato with head-to-hea...

Johnson & Johnson's Spravato therapy for treatment-resistant depression (TRD) hasn't made the impact the company hoped for in the market, and it is looking to new clinical results to ac

News

J&J, Idorsia plan filings for aprocitentan data in resistant...

People whose blood pressure remains stubbornly high despite current drug treatment and are at increased risk of complications such as kidney disease and stroke could have another treatment

News

Janssen leads effort to cut waste in digital health devices

A consortium of industry and academic groups – led by Johnson & Johnson's pharma division Janssen – has been set up to tackle the environmental impact of

Podcasts

How pharma can spur innovation and promote health equity in ...

In the newest episode of the pharmaphorum podcast, editor in chief Jonah Comstock speaks with Mohammed Issa, vice president of commercial at US Janssen Neuroscience.

Market Access

Saving lives doesn’t have to cost the Earth

Jamie Phares, managing director, The Janssen Pharmaceutical Companies of Johnson & Johnson in the Gulf Cooperation Council (GCC), talks about how the healthcare industry needs to come t

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J ducks out of Bavarian Nordic vaccine partnerships

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis

J&J builds case for antidepressant Spravato with head-to-hea...

J&J, Idorsia plan filings for aprocitentan data in resistant...

Janssen leads effort to cut waste in digital health devices

How pharma can spur innovation and promote health equity in ...

Saving lives doesn’t have to cost the Earth

J&J ducks out of Bavarian Nordic vaccine partnerships

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Janssen

Editor's Picks